Skip to content
Insider tapeLive · 5:07 PM ET
My stocks

Mark E. Bunnage

At a glance: Mark E. Bunnage is Evp, Chief Scientific Officer at Vertex Pharmaceuticals (VRTX). Their latest SEC Form 4, filed May 19, 2026, reported a sale of $15K. On file: 0 purchase lines ($0) and 5 sale lines ($3.0M).

Disclosed holdings: about $3.8M of VRTX stock: 7,284 shares reported on their latest Form 4 (filed May 19, 2026), valued at the Nov 19, 2026 close of $521.30. This counts only VRTX shares reported to the SEC; it leaves out cash, other investments, options and unvested awards, so it is not total net worth.

Evp, Chief Scientific Officer at Vertex Pharmaceuticals Inc / Ma (VRTX)

Purchase track record

Not enough history. Based on 0 purchases with a full 90 days of price history.

—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $3.0M

Mark E. Bunnage's InsiderPrint

5 trades from SEC Form 4 filings, 2026 to 2026, drawn as one fingerprint.

InsiderPrint of Mark E. Bunnage: 5 trades, 2026 to 20262026: 0 buys, 5 sales

Reading this print: Almost only sells, trading about 5 times a year, typically $560K a trade; most sales are on a pre-planned 10b5-1 schedule.

  • Bump outward: a purchase (0)
  • Dent inward: a sale (5)
  • One ring per year, oldest in the middle, Jan at the top going clockwise. Bigger bumps mean more dollars.

Insiders with a similar print

  1. Ingrid DelaetChief Regulatory Officer · NBIX · 100% match
  2. Shibu NinanChief Accounting Officer · OKTA · 100% match
  3. Christopher Scott EdmondsPresident · ICE · 100% match
  4. Edward Morrow Atkinson IIIEvp, Chief Technical Ops. Off. · VRTX · 100% match
  5. Eric A. Hughes"See ""Remarks""" · TEVA · 100% match

Matched on seven traits of each insider's trading pattern (buy share, pace, typical size, planned sales, seasonality, buying after drops, number of companies). Pattern matching on public filings; history, not a prediction.

Reported trades

Filed Stock Type Shares Price Value Since
May 19SEC VRTXVertex Pharmaceuticals Inc / Ma Sell Plan 337,284 held (−0%) $453.45 $15K +15.0%
Feb 26SEC VRTXVertex Pharmaceuticals Inc / Ma Sell Plan 6207,284 held (−8%) $486.35 $302K +7.2%
Feb 19SEC VRTXVertex Pharmaceuticals Inc / Ma Sell Plan 2,4379,668 held (−20%) $489.46 $1.2M +6.5%
Feb 19SEC VRTXVertex Pharmaceuticals Inc / Ma Sell Plan 1,1828,486 held (−12%) $473.68 $560K +10.1%
Feb 12SEC VRTXVertex Pharmaceuticals Inc / Ma Sell Plan 2,02112,914 held (−14%) $460.43 $931K +13.2%
  • Sell

    Evp, Chief Scientific Officer Mark E. Bunnage sold $15K of VRTX at $453.45 — pre-scheduled 10b5-1 plan sale.

  • Sell

    Evp, Chief Scientific Officer Mark E. Bunnage sold $302K of VRTX at $486.35 — pre-scheduled 10b5-1 plan sale.

  • Sell

    Evp, Chief Scientific Officer Mark E. Bunnage sold $1.2M of VRTX at $489.46 — pre-scheduled 10b5-1 plan sale.

  • Sell

    Evp, Chief Scientific Officer Mark E. Bunnage sold $560K of VRTX at $473.68 — pre-scheduled 10b5-1 plan sale.

  • Sell

    Evp, Chief Scientific Officer Mark E. Bunnage sold $931K of VRTX at $460.43 — pre-scheduled 10b5-1 plan sale.

Follow Mark E. Bunnage

Get one email when Mark E. Bunnage files a new purchase or sale. Free.

At most one email a day about Mark E. Bunnage, plus the free Monday email. Already subscribed? Use the same email to add them. Unsubscribe anytime. Facts from public filings, not advice.